Fast beneficial systemic anti-inflammatory effects of inhaled budesonide and formoterol on circulating lymphocytes in asthma

Respirology

Volumn 18, Issue 5, 2013, Pages 840-847

  Rüdiger, Jochen J ^a,b   Gencay, Mikael ^b   Yang, Jin Q ^b   Bihl, Michel ^b   Tamm, Michael ^b   Roth, Michael ^b  

^a Internal Medicine   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

asthma; budesonide; circulating lymphocyte; formoterol; systemic effect

Indexed keywords

BUDESONIDE; EOTAXIN; FORMOTEROL; GLUCOCORTICOID RECEPTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BLOOD SAMPLING; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADULT; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BUDESONIDE; CROSS-OVER STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MALE; NF-KAPPA B; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879405858     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12104     Document Type: Article

References (42)

1. Giembycz MA, Kaur M, Leigh R, et al. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br. J. Pharmacol. 2008; 153: 1090-1104.
2. Garcia-Marcos L, Ros-Lucas JA, Sanchez-Solis M,. Inhaled corticosteroids in asthmatic children: are they as safe in infants and preschoolers as in older children? A review. Curr. Drug Saf. 2008; 3: 35-45.
3. Mori H, Tanaka H, Ohno Y, et al. Effect of intermittent systemic corticosteroid on bone metabolism in bronchial asthma patients. J. Asthma 2009; 46: 142-146.
4. Pedersen S, Engelstätter R, Weber HJ, et al. Efficacy and safety of ciclesonide once daily and Fluticasone propionate twice daily in children with asthma. Pulm. Pharmacol. Ther. 2009; 22: 214-220.
5. Han ER, Choi IS, Kim HK, et al. Inhaled corticosteroid-related tooth problems in asthmatics. J. Asthma 2009; 46: 160-164.
6. Reinero CR, Brownlee L, Decile KC, et al. Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. J. Vet. Intern. Med. 2006; 20: 57-64.
7. Parikh NA, Locke RG, Chidekel A, et al. Effect of inhaled corticosteroids on markers of pulmonary inflammation and lung maturation in preterm infants with evolving chronic lung disease. J. Am. Osteopath. Assoc. 2004; 104: 114-120.
8. Xiong G, Xu L, Wei L, et al. Atomization inhalation of terbutaline and budesonide efficiently improved immunity and lung function of AECOPD patients. Cell. Mol. Immunol. 2008; 5: 287-291.
9. Taki H, Shinoda K, Hounoki H, et al. Serum interleukin-5 levels correlate with disease activity of Churg-Strauss syndrome in a patient treated with a leucotriene receptor antagonist, pranlukast, and inhaled corticosteroid. Scand. J. Rheumatol. 2010; 39: 341-343.
10. Koopmans JG, Lutter R, Jansen HM, et al. Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. J. Allergy Clin. Immunol. 2005; 116: 1007-1013.
11. Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J. Allergy Clin. Immunol. 2004; 114: 1425-1433.
12. Zhang Q, Qian FH, Liu H, et al. Expression of surface markers on peripheral CD4+CD25high T cells in patients with atopic asthma: role of inhaled corticosteroid. Chin. Med. J. (Engl.) 2008; 121: 205-212.
13. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 1207-1214.
14. Eickelberg O, Roth M, Lörx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 1999; 274: 1005-1010.
15. 2-agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293-1299.
16. Roth M, Johnson PR, Borger P, et al. Dysfunctional interaction of C/EBPα and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N. Engl. J. Med. 2004; 351: 560-574.
17. Rüdiger JJ, Roth M, Bihl MP, et al. Interaction of C/EBPα and the glucocorticoid receptor in vivo and in nontransformed human cells. FASEB J. 2002; 16: 177-184.
18. Oliver BG, Johnston SL, Baraket M, et al. Increased proinflammatory responses from asthmatic human airway smooth muscle cells in response to rhinovirus infection. Respir. Res. 2006; 7: 71-82.
19. Oliver BG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax 2008; 63: 519-525.
20. Yang JQ, Rüdiger JJ, Hughes JM, et al. Cell density and serum exposure modify the function of the glucocorticoid receptor C/EBP complex. Am. J. Respir. Cell Mol. Biol. 2008; 38: 414-422.
21. Lee JS, Kim IS, Ryu JS, et al. House dust mite, Dermatophagoides pteronissinus increases expression of MCP-1, IL-6, and IL-8 in human monocytic THP-1 cells. Cytokine 2008; 42: 365-371.
22. Renois F, Jacques J, Talmud D, et al. Respiratory echovirus 30 and coxsackievirus B5 can induce production of RANTES, MCP-1 and IL-8 by human bronchial epithelial cells. Virus Res. 2010; 152: 41-49.
23. Bathoorn E, Liesker JJ, Postma DS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int. J. Chron Obstruct. Pulm. Dis. 2009; 4: 101-109.
24. Gemou-Engesaeth V, Bush A, Kay AB, et al. Inhaled glucocorticoid therapy of childhood asthma is associated with reduced peripheral blood T cell activation and 'Th2-type' cytokine mRNA expression. Pediatrics 1997; 99: 695-703.
25. Dahlén B, Lantz AS, Ihre E, et al. Effect of formoterol with or without budesonide in repeated low-dose allergen challenge. Eur. Respir. J. 2009; 33: 747-753.
26. Davies JM, Carroll ML, Li H, et al. Budesonide and formoterol reduce early innate anti-viral immune responses in vitro. PLoS ONE 2011; 6: e27898.
27. Silvestri M, Morandi F, Pistoia V, et al. Ciclesonide modulates in vitro allergen-driven activation of blood mononuclear cells and allergen-specific T-cell blasts. Immunol. Lett. 2012; 141: 190-196.
28. Donnelly LE, Tudhope SJ, Fenwick PS, et al. Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages. Eur. Respir. J. 2010; 36: 178-186.
29. Menezes MB, Teixeira AL, Terra Filho J, et al. Inflammatory and functional effects of increasing asthma treatment with formoterol or double dose budesonide. Respir. Med. 2008; 102: 1385-1391.
30. Drazen JM, O'Byrne PM,. Risks of long-acting beta-agonists in achieving asthma control. N. Engl. J. Med. 2009; 360: 1671-1672.
31. Nalson HS, Weiss ST, Bleecker ER, et al., SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
32. Patel JK, Clifford RL, Deacon K, et al. Ciclesonide inhibits TNFα- and IL-1β-induced monocyte chemotactic protein-1 (MCP-1/CCL2) secretion from human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012; 302: L785-792.
33. Redhu NS, Saleh A, Lee HC, et al. IgE induces transcriptional regulation of thymic stromal lymphopoietin in human airway smooth muscle cells. J. Allergy Clin. Immunol. 2011; 128: 892-6.e2.
34. Liberman AC, Druker J, Perone MJ, et al. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 2007; 18: 45-56.
35. Liberman AC, Antunica-Noguerol M, Ferraz-de-Paula V, et al. Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells. PLoS ONE 2012; 7: e35155.
36. McMaster A, Ray DW,. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. Exp. Physiol. 2007; 92: 299-309.
37. Reddy PJ, Aksoy MO, Yang Y, et al. Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells. COPD 2008; 5: 5-11.
38. Ito K, Herbert C, Siegle JS, et al. Steroid-Resistant Neutrophilic Inflammation in a Mouse Model of an Acute Exacerbation of Asthma. Am. J. Respir. Cell Mol. Biol. 2008; 39: 543-550.
39. Schwindt CD, Zaldivar F, Eliakim A, et al. Inhaled Fluticasone and the hormonal and inflammatory response to brief exercise. Med. Sci. Sports Exerc. 2010; 42: 1802-1808.
40. Ammit AJ, Moir LM, Oliver BG, et al. Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 292: L199-206.
41. Scheicher ME, Teixeira MM, Cunha FQ, et al. Eotaxin-2 in sputum cell culture to evaluate asthma inflammation. Eur. Respir. J. 2007; 29: 489-495.
42. 2-adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J. Immunol. 2005; 175: 478-486.